Quick Answer
Solid Biosciences Inc. reported Diluted EPS of $1.99 per share (loss) for fiscal year 2025.
Solid Biosciences Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.99 | +35.0% |
| 2024 | -$3.06 | +36.6% |
| 2023 | -$4.83 | +52.2% |
| 2022 | -$10.10 | +0.4% |
| 2021 | -$10.14 | +60.2% |
| 2020 | -$25.50 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.48 | +39.2% | -14.3% |
| June 30, 2025 | -$0.42 | +31.1% | +0.0% |
| March 31, 2025 | -$0.42 | +34.4% | +46.8% |
| September 30, 2024 | -$0.79 | +24.8% | -29.5% |
| June 30, 2024 | -$0.61 | +51.2% | +4.7% |
| March 31, 2024 | -$0.64 | +58.4% | +39.0% |
| September 30, 2023 | -$1.05 | +61.3% | +16.0% |
| June 30, 2023 | -$1.25 | +62.5% | +18.8% |
- Solid Biosciences Inc. showed an increase of +35.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Solid Biosciences Inc.’s diluted eps has grown by 92.2% (from $25.50 per share (loss) to $1.99 per share (loss)).
- The most recent figure is from Solid Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: